| Primary |
| Product Used For Unknown Indication |
30.9% |
| Staphylococcal Infection |
10.4% |
| Cellulitis |
9.1% |
| Osteomyelitis |
8.0% |
| Pneumonia |
6.7% |
| Infection |
5.7% |
| Endocarditis |
3.7% |
| Sepsis |
2.8% |
| Staphylococcal Bacteraemia |
2.8% |
| Drug Use For Unknown Indication |
2.5% |
| Device Related Infection |
2.3% |
| Pyrexia |
2.2% |
| Pain |
2.0% |
| Prophylaxis |
1.9% |
| Febrile Neutropenia |
1.7% |
| Antibiotic Prophylaxis |
1.5% |
| Bacterial Infection |
1.5% |
| Wound Infection |
1.5% |
| Anaesthesia |
1.3% |
| Evidence Based Treatment |
1.3% |
|
| Renal Failure Acute |
15.6% |
| Rash |
10.1% |
| Drug Hypersensitivity |
6.8% |
| Urticaria |
5.9% |
| Red Man Syndrome |
5.7% |
| Thrombocytopenia |
5.5% |
| Blood Creatinine Increased |
4.9% |
| Linear Iga Disease |
4.5% |
| Pruritus |
4.5% |
| Renal Tubular Necrosis |
4.4% |
| Nephropathy Toxic |
4.3% |
| Pyrexia |
3.8% |
| Neutropenia |
3.5% |
| Toxic Epidermal Necrolysis |
3.5% |
| White Blood Cell Count Decreased |
3.3% |
| Tubulointerstitial Nephritis |
3.1% |
| Rash Erythematous |
2.8% |
| Vomiting |
2.8% |
| Hypotension |
2.6% |
| Renal Tubular Disorder |
2.3% |
|
| Secondary |
| Product Used For Unknown Indication |
24.8% |
| Drug Use For Unknown Indication |
15.4% |
| Sepsis |
6.1% |
| Infection |
6.1% |
| Staphylococcal Infection |
4.9% |
| Pneumonia |
4.9% |
| Hypertension |
4.7% |
| Prophylaxis |
3.8% |
| Pyrexia |
3.7% |
| Device Related Infection |
3.0% |
| Endocarditis |
2.9% |
| Acute Myeloid Leukaemia |
2.7% |
| Osteomyelitis |
2.6% |
| Pain |
2.5% |
| Bacteraemia |
2.4% |
| Cataract Operation |
2.2% |
| Acute Lymphocytic Leukaemia |
1.9% |
| Antibiotic Therapy |
1.9% |
| Cellulitis |
1.8% |
| Meningitis |
1.7% |
|
| Renal Failure Acute |
13.7% |
| Toxic Epidermal Necrolysis |
11.7% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
9.4% |
| Thrombocytopenia |
7.2% |
| Pyrexia |
6.2% |
| Toxic Skin Eruption |
5.6% |
| Renal Failure |
4.9% |
| Tubulointerstitial Nephritis |
4.6% |
| Stevens-johnson Syndrome |
3.8% |
| Septic Shock |
3.8% |
| Staphylococcal Infection |
3.8% |
| Vomiting |
3.5% |
| White Blood Cell Count Decreased |
3.5% |
| Renal Impairment |
3.1% |
| Rash |
3.0% |
| Sepsis |
2.6% |
| Toxic Anterior Segment Syndrome |
2.6% |
| Myocardial Infarction |
2.5% |
| Blood Creatinine Increased |
2.3% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
45.0% |
| Drug Use For Unknown Indication |
18.7% |
| Prophylaxis |
6.0% |
| Pain |
3.0% |
| Hypertension |
2.8% |
| Acute Myeloid Leukaemia |
2.8% |
| Coronary Artery Bypass |
2.3% |
| Sepsis |
2.1% |
| Pyrexia |
2.1% |
| Infection |
2.0% |
| Pneumonia |
1.9% |
| Acute Lymphocytic Leukaemia |
1.9% |
| Infection Prophylaxis |
1.5% |
| Multiple Myeloma |
1.4% |
| Staphylococcal Infection |
1.4% |
| Nausea |
1.2% |
| Febrile Neutropenia |
1.1% |
| Constipation |
1.0% |
| Adverse Event |
1.0% |
| Sedation |
0.9% |
|
| Vomiting |
9.1% |
| Sepsis |
8.6% |
| Thrombocytopenia |
7.8% |
| Renal Failure |
6.1% |
| White Blood Cell Count Decreased |
5.8% |
| Pyrexia |
5.5% |
| Renal Failure Acute |
5.5% |
| Injury |
5.3% |
| Pain |
5.3% |
| Weight Decreased |
4.6% |
| Pneumonia |
4.3% |
| Respiratory Failure |
4.2% |
| Unevaluable Event |
4.2% |
| Death |
4.0% |
| Anxiety |
3.5% |
| Fear |
3.4% |
| Septic Shock |
3.3% |
| Multi-organ Failure |
3.2% |
| White Blood Cell Count Increased |
3.1% |
| Urinary Tract Infection |
3.1% |
|
| Interacting |
| Bronchopulmonary Aspergillosis |
31.3% |
| Prophylaxis |
10.4% |
| Aspergillosis |
10.0% |
| Stem Cell Transplant |
8.0% |
| Endocarditis |
7.0% |
| Grand Mal Convulsion |
4.0% |
| Sepsis |
4.0% |
| Osteitis |
3.0% |
| Postoperative Care |
3.0% |
| Product Used For Unknown Indication |
3.0% |
| Antiplatelet Therapy |
2.0% |
| Candidiasis |
2.0% |
| Diabetes Mellitus |
2.0% |
| Drug Use For Unknown Indication |
2.0% |
| Graft Versus Host Disease |
2.0% |
| Premedication |
2.0% |
| Septic Embolus |
1.5% |
| Arthritis Infective |
1.0% |
| Bacterial Infection |
1.0% |
| Cardiac Disorder |
1.0% |
|
| Drug Interaction |
21.6% |
| Immunosuppressant Drug Level Decreased |
19.6% |
| Sepsis |
13.7% |
| Hypersensitivity |
11.8% |
| Renal Failure Acute |
9.8% |
| Overdose |
5.9% |
| Mucocutaneous Candidiasis |
3.9% |
| Hypokalaemia |
2.0% |
| Infection |
2.0% |
| Papule |
2.0% |
| Proteus Infection |
2.0% |
| Rash Erythematous |
2.0% |
| Status Epilepticus |
2.0% |
| Urticaria |
2.0% |
|